Know Cancer

forgot password

Phase 1, Open Label, Multi-Center Study To Evaluate The Safety And Tolerability of CT-322 Administered In Combination With Focal Brain Radiotherapy And Temozolomide To Subjects With Newly Diagnosed Glioblastoma Multiforme

Phase 1
18 Years
Open (Enrolling)
Glioblastoma Multiforme

Thank you

Trial Information

Phase 1, Open Label, Multi-Center Study To Evaluate The Safety And Tolerability of CT-322 Administered In Combination With Focal Brain Radiotherapy And Temozolomide To Subjects With Newly Diagnosed Glioblastoma Multiforme

Inclusion Criteria:

- Informed consent

- 18 years or older

- Newly diagnosed, histologically confirmed GBM (grade IV astrocytoma):

- Subjects will not be eligible if the original histology was a lower grade glioma
and a subsequent histological diagnosis of a GBM is made

- Central independent pathology confirmation of GBM, concurrent with subject

- Subjects with sufficient biopsy material available to perform PCR analysis for
MGMT promoter methylation must have tissue submitted to the designated
laboratory for analysis. Subjects with insufficient tissue or indeterminate
results will remain eligible for enrollment.

- KPS ≥ 60

- Be able to begin treatment with RT/TMZ within 6 weeks after biopsy or craniotomy with
satisfactory wound healing prior to initiating treatment with CT-322

- Be able to undergo serial MRIs:

- Measurable or assessable disease may or may not be present

- CT scanning may not substitute for MRI scanning

- Have adequate bone marrow, liver, renal, and metabolic function as assessed by the

- Hemoglobin ≥ 10.0 g/dL (unsupported)

- Absolute neutrophil count (ANC) ≥ 1,500/mm3 (unsupported)

- Platelet count ≥ 100,000/mm3 (unsupported)

- Total bilirubin ≤ 1.5 x ULN, unless due to Gilbert's disease

- ALT and AST ≤ 3 x ULN

- INR < 1.5 or PT within normal limits; and PTT within normal limits

- Serum creatinine ≤ 1.5 x ULN

- Urine protein/creatinine ratio (UPCR) < 1.0

- Serum amylase and lipase ≤ 1.5 x the ULN

- 2-dimensional echo or MUGA scan with LVEF within the institutional normal range

- Stable or decreasing dose of corticosteroids for at least 1 week prior to screening

- Contraceptive measures for male and female participants for the duration of treatment
and for 4 weeks following discontinuation of study treatment:

--Female subjects having reproductive potential must have a negative serum pregnancy
test within 72 hours before first administration of CT-322

- Be able to comply with scheduled visits, treatment plan, laboratory tests, and other
study procedures including receiving daily external beam RT in a radiation treatment

- integral to or affiliated with the investigative site and in which the treating
radiation therapist is a participating study investigator; and

- that has agreed to follow the radiation treatment guidance and complete the
radiation treatment data collection forms

Exclusion Criteria:

- Prior CT-322 therapy or prior therapy with another VEGF-modulating agent (marketed or
investigational) for malignant glioma

- History of hypersensitivity to TMZ or any of its excipients, or to Dacarbazine (DTIC)

- Prior treatment for GBM, except surgical resection and/or corticosteroid therapy

- Prior radiotherapeutic, or local (intra-tumoral) or systemic medical therapies
(including but not limited to: chemotherapy, hormonal therapy, immunotherapy,
anti-angiogenic therapy, implantable Gliadel® wafers, and molecularly targeted
therapy) for brain tumors

- Current enrollment in another therapeutic clinical trial involving ongoing therapy

- Concurrent severe and/or uncontrolled medical disease that could compromise
participation in the study such as:

- Pleural or pericardial effusion of ≥ grade 2

- Uncontrolled diabetes, despite optimal medical management, according to the
opinion of the investigator

- Uncontrolled hypertension (defined as systolic blood pressure > 150 mmHg or
diastolic pressure > 90 mmHg, despite optimal medical management)

- Any active craniotomy-related wound infection

- Active clinically significant infection (> grade 2 by National Cancer Institute
(NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE) requiring the
use of anti-microbial agents, or that would be otherwise, in the opinion of the
investigator, interfere with the ability of the subject to participate

- History of clinically significant bleeding diathesis or coagulopathy including
platelet function disorder (e.g., known hemophilia or von Willebrand disease) or
acquired bleeding disorder within one year (e.g., acquired anti-factor VIII

- Ongoing or recent (≤ 3 months) significant gastrointestinal bleeding untreated
or recurring

- Untreated peptic ulcer disease or peptic ulcer disease treated for < 3 months

- Non-healing wound (including craniotomy wound), ulcer, or bone fracture; or

- Glomerulonephritis or other protein-wasting glomerulopathy

- Within 12 months before enrollment had:

- Thrombotic or embolic cerebrovascular accident or transient ischemic attacks

- CNS bleed (other than stable, grade 1)

- Intraocular bleed, or any medical condition, which in the opinion of the
investigator increases the risk for intra-ocular bleeding

- Septic endocarditis (unless deemed cured and off all antibiotic therapy for at
least 3 months)

- Coronary artery bypass graft, angioplasty, vascular stenting, myocardial
infarction, unstable angina; or

- Symptomatic congestive heart failure (New York Heart Association ≥ class II)

- Any intraparenchymal CNS hemorrhage at the time of enrollment except for:

- Grade 1 intraparenchymal hemorrhage in the immediate post-operative period, or

- Grade 1 intraparenchymal hemorrhage that has been stable (no significant change
on 2 consecutive MRI scans at least 4 weeks apart) or improved

- Subjects with a history of prior cardiotoxic chemotherapy exposure or subjects with
thoracic irradiation involving cardiac tissue

- Other, non-glioma related major surgery, open biopsy, or significant traumatic injury
within 4 weeks before the first dose of CT-322

--Placement of subcutaneous in-dwelling venous access port within 2 weeks before the
first dose of CT-322

- Known human immunodeficiency virus infection or known active acute or chronic viral

- Prior malignancy within the previous 3 years, except adequately treated basal cell
skin cancer or cervical carcinoma in situ; or if the other primary malignancy is not
currently clinically significant or requiring active intervention

- Has any other severe, acute, or chronic medical or psychiatric condition, or
laboratory abnormality that could increase the risks associated with study
participation or study drug administration or could interfere with the interpretation
of the study results and, in the judgment of the investigator, would make the subject
inappropriate for entry in this study or non-compliant with study-related procedures

- Subjects with medical conditions that would not permit, in the judgment of the
investigator, the safe discontinuation of medications that are prohibited throughout
the course of the study

- Any condition requiring therapeutic anti-coagulation with either oral (e.g., warfarin
type) or injectable anti-coagulants; however, low-dose (i.e., 1 mg daily [QD])
warfarin is permitted for venous port patency maintenance

- Females who are pregnant or breast feeding.

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Evaluate the safety and tolerability of CT-322 administered in combination with standard focal brain RT/TMZ to subjects with newly diagnosed GBM

Outcome Time Frame:

15 ± 5 days post the last dose of study drug

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

October 2008

Completion Date:

June 2011

Related Keywords:

  • Glioblastoma Multiforme
  • glioblastoma
  • Glioblastoma multiforme (newly diagnosed)
  • Glioblastoma



University of Arkansas for Medical SciencesLittle Rock, Arkansas  72205
Duke University Medical CenterDurham, North Carolina  27710
SUNY Upstate Medical UniversitySyracuse, New York  13210
University of Chicago Medical CenterChicago, Illinois  60637
University of Kentucky HospitalLexington, Kentucky  40536
Washington University Cancer CenterSt. Louis, Missouri  63110